

Press Release

WaveLight AG: New FDA approval expands treatment range of the ALLEGRETTO WAVE Eye-Q

Additional market and sales potential expected in the United States

New manpower at U.S. subsidiary WaveLight Inc.

Erlangen, April 17, 2007. WaveLight AG has received the approval of the U.S. Food and Drug Administration (FDA) for its 400-Hz ALLEGRETTO WAVE Eye-Q laser system for wavefront-guided LASIK treatments and to treat mixed astigmatism.

In July 2006, the ALLEGRETTO WAVE Eye-Q was approved by the FDA for performing LASIK procedures to correct farsightedness, nearsightedness, and astigmatism.

The additional FDA approval now granted allows the excimer laser – which features world-leading technology – to also be used in particular for high-precision correction of more complex visual limitations, such as the treatment of mixed astigmatism. For patients with this type of visual disorder, both nearby and more distant objects appear blurred. The ALLEGRETTO WAVE Eye-Q thus covers the entire range of treatments in the area of refractive surgery as well as wavefront-optimized and wavefront-guided procedures to correct visual disorders.

Thanks to the ALLEGRETTO WAVE, which has already been installed well over 100 times in U.S. medical practices and clinics and which offers a 200-Hz repetition rate, plus its technologically enhanced “big brother,” the 400-Hz ALLEGRETTO WAVE Eye-Q model, WaveLight not only has superior technology to its competitors, but also the most comprehensive range of approved products in the United States. On this basis, the Company is expecting a further improvement in its market position in North America in the coming fiscal year.

WaveLight Inc. makes personnel changes at management level

As part of WaveLight Inc.’s strategic and human resources realignment at the beginning of the current fiscal year, the management team around CEO Wolfgang Tolle was expanded to further boost the company’s sales and marketing activities in the United States.

“We are extremely confident that we can continue to significantly strengthen our market position in the United States in the current fiscal year 2006/2007. The expansion of the approved range of treatments offered by the ALLEGRETTO WAVE Eye-Q and the new manpower in the U.S. team provide an excellent basis for this,” said Max Reindl, CEO of WaveLight AG, commenting on development prospects in the United States.

WaveLight AG (ISIN DE 000 512 5603)

WaveLight AG, listed in Deutsche Börse AG's Prime Standard since January 2003, develops, produces, and markets a high-quality, end-to-end product portfolio in the field of ophthalmology. As a specialist in optical technology, WaveLight's market success is based on its innovative range of products that are the technology leaders in their areas of application and its broad-based sales network featuring both own sales channels and strategic partners.

Further information on WaveLight is available at: www.wavelight.com

Press contacts:

Susanne Grethlein
WaveLight AG
Tel: + 49/9131/6186-103
Fax: +49/9131/6186 -112
E-mail: susanne.grethlein@wavelight.com

Gerhard Lodzwick
AGIL Gesellschaft für Finanzkommunikation mbH
Tel: +49/2131/12 55 73
Fax: +49/2131/12 557 55
E-mail: info@agil-ir.com

Disclaimer:

Some of the statements made in this disclosure take the form of forecasts or could be interpreted as such. All information is given and all assessments are made on the basis of extremely conscientious research. However, no guarantee is given with regard to the information or assessments published. No liability whatsoever is accepted. The above statements do not represent an invitation to buy or sell securities. All rights reserved.